Table 2.
Dosing characteristics per cycle.
| All cycles(N=33,962) | Constant dose (N=20,139) | Dose changes (N=13,823) | Dose increase a (N=7,939) | Dose decrease b (N=8,639) | Dose increasesand decreases c (N=2,755) | |
|---|---|---|---|---|---|---|
| GnRH use, n (%) | ||||||
| Agonist | 13435 (39.6) | 8008 (39.8) | 5427 (39.3) | 2835 (35.7) | 3601 (41.7) | 1009 (36.6) |
| Antagonist | 20231 (59.6) | 11921 (59.2) | 8310 (60.1) | 5036 (63.4) | 4987 (57.7) | 1713 (62.2) |
| None or unknown | 296 (0.9) | 210 (1.0) | 86 (0.6) | 68 (0.9) | 51 (0.6) | 33 (1.2) |
| Use of LH-like product, n (%) | ||||||
| No, r-hFSH-alfa only | 1,390 (4.1) | 895 (4.4) | 495 (3.6) | 207 (2.6) | 377 (4.4) | 89 (3.2) |
| Yes d | 32,572 (95.9) | 19,244 (95.6) | 13,328 (96.4) | 7,732 (97.4) | 8,262 (95.6) | 2,666 (96.8) |
| hMG | 29,639 (87.3) | 17,480 (86.8) | 12,159 (88.0) | 7,226 (91.0) | 7,431 (86.0) | 2,498 (90.7) |
| micro-dose hCG | 2,724 (8.0) | 1,612 (8.0) | 1,112 (8.0) | 477 (6.0) | 784 (9.1) | 149 (5.4) |
| r-hLH | 557 (1.6) | 363 (1.8) | 194 (1.4) | 104 (1.3) | 124 (1.4) | 34 (1.2) |
| r-hFSH-alfa treatment characteristics | ||||||
| Starting dose | 275.87 (130.99) | 292.47 (133.24) | 251.69 (123.73) |
237.76 (122.58) |
257.98 (133.28) | 231.28 (149.88) |
| Ending dose | 255.33 (137.61) | 265.72 (135.25) | 240.20 (139.60) |
294.86 (130.20) |
183.15 (121.62) | 218.80 (125.75) |
| Total dose | 2,838.1 (1,537.6) | 2,916.0 (1,567.9) | 2,724.5 (1,485.1) |
3135.4 (1,506.4) |
2,271.7 (1,295.5) | 2488.8 (1,345.3) |
| Minimum dose | 227.62 (123.89) | 260.01 (127.43) | 191.24 (108.86) |
213.52 (102.24) |
160.26 (105.74) | 158.31 (95.32) |
| Average dose | 282.57 (133.40) | 294.81 (137.77) | 265.19 (124.89) |
293.71 (121.67) |
230.66 (117.46) | 233.66 (112.78) |
N is the number of cycles in each dosing pattern. Data are presented as mean (SD) IU unless stated otherwise.
GnRH, gonadotropin-releasing hormone.
a
Includes all cycles with at least one dose increase (regardless of any decrease).
b
Includes all cycles with at least one dose decrease (regardless of any increase).
c
Includes all cycles with at least one dose increase and one dose decrease.
d
Patients could have been prescribed >1 LH-like product.